Indivior PLC INVVY
21.85 0.00 (+0.00%)
Jun 9, 2023, 10:23 AM EDT
21.85 Day range 21.85
14.76 52-week range 75.65
- Market cap
- 3.01B
- EPS (ttm)
- -0.35
- P/E ratio
- -62.42
- Volume
- 8.10K
- Avg volume
- 3.71K
- Open
- 21.65
- Previous close
- 21.85
- Day's range
- 21.85 – 21.85
- 52-week range
- 14.76 – 75.65
- Earnings date
- Jun 15, 2023
No chart data for this range yet.
Next earnings
Jun 15, 2023
Expected Jun 15, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Jan 4, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Jul 28, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| Apr 28, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 16, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
News
Why Indivior Pharmaceuticals Stock Topped the Market Today 
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader 
Indivior Reports Third Quarter 2026 Financial Results 
Indivior to Report Third Quarter 2026 Financial Results 
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior 
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend 
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders 
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 
Indivior (OTCMKTS:INVVY) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell? 
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Your note
Sign in to keep a note on INVVY — it syncs with the Stock Master app.